GSK-3 Inhibitors: A Double-Edged Sword? - An Update on Tideglusib.
| Autor: | Mathuram TL; Department of Stem Cell and Tissue Engineering, Frontier Mediville (A Unit of Frontier Lifeline and Dr. K. M. Cherian Heart Foundation), Affiliated to University of Madras, Chennai, Tamil Nadu, India., Reece LM; Sealy Center for Vaccine Development, World Health Organization Collaborating Center for Vaccine Research, Evaluation and Training on Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA., Cherian KM; Department of Cardiothoracic Surgery, Frontier Lifeline Hospital, Chennai, Tamil Nadu, India. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Drug research [Drug Res (Stuttg)] 2018 Aug; Vol. 68 (8), pp. 436-443. Date of Electronic Publication: 2018 Jan 31. |
| DOI: | 10.1055/s-0044-100186 |
| Abstrakt: | GSK-3 inhibitors are an emerging tool for clinical interventions in human diseases and represent a niche area in combinational therapy. They possess diverse facets in applications of nervous system disorders, Type 2 diabetes, regenerative medicine and cancer. However, conflicting reports suggest the controversial role of GSK-3 inhibitors in cancers. This review aims to highlight the rise of GSK-3 inhibitors as tools for molecular-targeted research and its shift to a promising drug candidate. The review also focuses on key GSK-3 inhibitors and their roles in cancer and regenerative medicine with special emphasis to tideglusib. In addition, the decisive roles of GSK-3 in various molecular pathways will be concisely reviewed. Finally, this review concludes the emergence of GSK-3 inhibitors as a 'double-edged sword' in the treatment against human diseases cautioning researchers about the potential ramifications of off-target pharmacological effects. Competing Interests: The authors declare no conflict of interest. (© Georg Thieme Verlag KG Stuttgart · New York.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|